[Form 4] Frontier Group Holdings, Inc. Insider Trading Activity
Robert J. Genise, a director of Frontier Group Holdings, Inc. (ULCC), sold 30,000 shares of the company’s common stock on 09/02/2025 at a weighted average price of $5.5174 per share (sales ranged $5.51–$5.53). After the reported transactions, the reporting person beneficially owned 330,534 shares. The Form 4 indicates the sale was reported on a single line and was signed by an attorney-in-fact for the reporting person.
- Transparent pricing disclosure including weighted average price $5.5174 and stated price range $5.51–$5.53
- Complete Section 16 reporting showing the director reported the sale on Form 4 and committed to provide per-trade details on request
- Insider sale reduced holdings by 30,000 shares from approximately 360,534 to 330,534 (a decrease of ~8.3%)
- No disclosure of a Rule 10b5-1 plan or reason for sale, so investors lack context for the director's disposition
Insights
TL;DR: A director executed a modest insider sale reducing holdings by about 8.3% at a ~$5.52 weighted average price.
The reported transaction is a non-derivative sale of 30,000 common shares, leaving the director with 330,534 shares. The disclosure provides the weighted average price and a price range ($5.51–$5.53) and commits to provide detailed per-trade pricing on request. From an investor-disclosure perspective this is routine Section 16 reporting: the filing is complete for the sale and shows transparent pricing information. The sale size is measurable relative to the reported post-transaction stake, but the Form 4 does not disclose any insider plan, reason for sale, or any derivative transactions.
TL;DR: Proper Form 4 compliance was observed; transaction appears straightforward with adequate pricing disclosure.
The filing identifies the reporting person as a director and reports the disposition clearly with a weighted average price plus a stated price range and an explicit offer to provide per-trade details. The form indicates a single reporting person filed the Form 4 and includes an attorney-in-fact signature. There is no amendment indicated and no accompanying derivative or plan-based transactions disclosed, limiting governance implications to the disclosed open-market sale.